From 941b5caeb5c79b2d2021a67f5641a050c522398b Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Tue, 20 Feb 2024 12:31:07 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web___Update 2024___02.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/pages/STOP2030___Web___Update 2024___02.md b/pages/STOP2030___Web___Update 2024___02.md index 0cfa9cc5..7617c918 100644 --- a/pages/STOP2030___Web___Update 2024___02.md +++ b/pages/STOP2030___Web___Update 2024___02.md @@ -86,5 +86,5 @@ - ### Background - Especificar que la novel formulation es una fixed-dose coformulation de [[Ivermectina]] y [[Albendazol]]. - Especificar que esta fixed-dose coformulation de ivm/alb has the lowest [[level]] of investment risk of all candidates for Combinations for [[STH]] treatment (fuente: Soil Transmitted Helminths Drug Combinations Expert Meeting, 2016, Gates Foundation) - - El ALIVE trial protocol: https://gatesopenresearch.org/articles/6-62/v1 + - Una referencia específica : https://gatesopenresearch.org/articles/6-62/v1 - \ No newline at end of file